DataMEDS AI Jumps as Helomics Acquisition Expands Its Push Into Cancer Diagnostics

By: Quiver PriceTracker

Posted: 2 hours ago / Sept. 16, 2026 2:50 p.m. UTC

MEDS

DataMeds AI, Inc. (MEDS) is up 242.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is DataMEDS’ September 15, 2026 announcement that it completed the acquisition of Helomics, an AI-driven cancer diagnostics lab and precision oncology CRO business, from Axe Compute. The deal appears to have excited traders because it adds a CLIA/CAP-certified laboratory, expands the company beyond pharmacy and health IT, and includes cash that management said can support growth initiatives.

Details:

DataMEDS announced it acquired Helomics for total consideration of $1.5 million, paid through common shares and an acquisition note.

The company said it also received Helomics’ CLIA/CAP-certified clinical laboratory, related equipment, the CRO central lab services business, and $1.5 million in cash.

Management framed the transaction as a step into cancer management and precision oncology, broadening the company’s operating footprint beyond its existing pharmacy, data, and healthcare technology activities.

Recent company materials had already highlighted plans to expand into diagnostic laboratory services, so this acquisition may be viewed as accelerating that strategy.

Sources:

ACCESS Newswire, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive MEDS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.